THE STAMFORD HOSPITAL
- Type
- Teaching hospital
- Where
- Stamford, CT
- Medicare CCN
- 070006
- Received
- $711,278 in 79 records, 2025 ($27,781 general, $683,497 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: STAMFORD HOSPITAL Fuzzy (name and state)
- Plan sponsor: STAMFORD HOSPITAL Fuzzy (name and state)
- Federal award recipient: STAMFORD HOSPITAL Fuzzy (name and state)
- Federal award recipient: STAMFORD HOSPITAL Fuzzy (name and state)
- Lobbying client: STAMFORD HOSPITAL Fuzzy (name and state)
- Lobbying client: STAMFORD HOSPITAL Fuzzy (name and state)
- Nonprofit: STAMFORD HOSPITAL Fuzzy (name and state)
- Trademark owner: The Stamford Hospital Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 34 | $27,781 |
| 2025 | Research payment | 45 | $683,497 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| PFIZER INC. | 15 | $240,732 | 2025 |
| Merck Sharp & Dohme LLC | 2 | $238,674 | 2025 |
| E.R. Squibb & Sons, L.L.C. | 3 | $135,294 | 2025 |
| Sumitomo Pharma America, Inc. | 11 | $26,097 | 2025 |
| Novartis Pharmaceuticals Corporation | 3 | $17,469 | 2025 |
| Genentech, Inc. | 7 | $16,104 | 2025 |
| Insulet Corporation | 21 | $13,625 | 2025 |
| Incyte Corporation | 2 | $5,060 | 2025 |
| Baxter Healthcare | 1 | $3,179 | 2025 |
| BIOTRONIK INC. | 1 | $3,000 | 2025 |
| AstraZeneca Pharmaceuticals LP | 1 | $3,000 | 2025 |
| Eli Lilly and Company | 1 | $2,565 | 2025 |
| Fisher Scientific Company L.L.C. | 2 | $2,034 | 2025 |
| Celgene Corporation | 1 | $1,500 | 2025 |
| Tandem Diabetes Care, Inc. | 4 | $1,400 | 2025 |
| Bioventus LLC | 2 | $1,283 | 2025 |
| Olympus America Inc. | 2 | $258 | 2025 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 45 | $683,497 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 25 | $15,025 |
| Debt forgiveness | 8 | $9,756 |
| Space rental or facility fees (teaching hospital only) | 1 | $3,000 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Merck Sharp & Dohme LLC | $135,469 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatm | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $103,204 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable | 2025 |
| 2025-12-31 | PFIZER INC. | $1,845 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2025 | |
| 2025-12-31 | Fisher Scientific Company L.L.C. | $740 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-12-24 | PFIZER INC. | $1,845 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2025 | |
| 2025-12-17 | PFIZER INC. | $18,459 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2025 | |
| 2025-12-16 | PFIZER INC. | $21,536 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2025 | |
| 2025-11-30 | BIOTRONIK INC. | $3,000 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-11-27 | PFIZER INC. | $13,697 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2025 | |
| 2025-11-19 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-11-10 | Novartis Pharmaceuticals Corporation | $1,131 | Research payment | In-kind items and services | A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety an | 2025 | |
| 2025-11-05 | Sumitomo Pharma America, Inc. | $1,021 | Research payment | Cash or cash equivalent | ORGOVYX Drug, PROSTATE CANCER | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2025 |
| 2025-11-05 | Sumitomo Pharma America, Inc. | $1,021 | Research payment | Cash or cash equivalent | ORGOVYX Drug, PROSTATE CANCER | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2025 |
| 2025-11-05 | Sumitomo Pharma America, Inc. | $1,021 | Research payment | Cash or cash equivalent | ORGOVYX Drug, PROSTATE CANCER | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2025 |
| 2025-11-05 | Sumitomo Pharma America, Inc. | $1,021 | Research payment | Cash or cash equivalent | ORGOVYX Drug, PROSTATE CANCER | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2025 |
| 2025-11-05 | Sumitomo Pharma America, Inc. | $1,021 | Research payment | Cash or cash equivalent | ORGOVYX Drug, PROSTATE CANCER | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2025 |
| 2025-11-05 | Sumitomo Pharma America, Inc. | $1,021 | Research payment | Cash or cash equivalent | ORGOVYX Drug, PROSTATE CANCER | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2025 |
| 2025-11-05 | Sumitomo Pharma America, Inc. | $1,021 | Research payment | Cash or cash equivalent | ORGOVYX Drug, PROSTATE CANCER | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2025 |
| 2025-10-29 | Insulet Corporation | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-10-23 | Genentech, Inc. | $985 | Research payment | Cash or cash equivalent | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | 2025 | |
| 2025-10-22 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-09-24 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-09-10 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-09-03 | PFIZER INC. | $58,317 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2025 | |
| 2025-08-29 | Olympus America Inc. | $238 | Debt forgiveness | In-kind items and services | Single Use Aspiration Needle NA-U401SX Device, Endotherapy | 2025 | |
| 2025-08-27 | Insulet Corporation | $1,475 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-08-20 | PFIZER INC. | $541 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2025 | |
| 2025-08-19 | Bioventus LLC | $641 | Debt forgiveness | In-kind items and services | 2025 | ||
| 2025-08-19 | Bioventus LLC | $641 | Debt forgiveness | In-kind items and services | 2025 | ||
| 2025-08-04 | Incyte Corporation | $2,530 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo | 2025 | |
| 2025-07-30 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2025 | |
| 2025-07-28 | Eli Lilly and Company | $2,565 | Research payment | Cash or cash equivalent | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS V | 2025 | |
| 2025-07-24 | Incyte Corporation | $2,530 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants | 2025 | |
| 2025-07-24 | Genentech, Inc. | $1,635 | Research payment | Cash or cash equivalent | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | 2025 | |
| 2025-07-23 | PFIZER INC. | $436 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2025 | |
| 2025-07-22 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-07-15 | Insulet Corporation | $375 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-07-08 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-07-03 | E.R. Squibb & Sons, L.L.C. | $8,250 | Research payment | Cash or cash equivalent | Connect MM: The Multiple Myeloma Disease Registry. The purpose of the Connect MM Registry is to explore the natural hist | 2025 | |
| 2025-07-01 | Insulet Corporation | $925 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-06-30 | Olympus America Inc. | $20 | Debt forgiveness | In-kind items and services | 2025 | ||
| 2025-06-21 | PFIZER INC. | $1,489 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2025 | |
| 2025-06-18 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2025 | |
| 2025-06-06 | PFIZER INC. | $43,383 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2025 | |
| 2025-06-03 | Insulet Corporation | $375 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-05-27 | Genentech, Inc. | $9,753 | Research payment | Cash or cash equivalent | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | 2025 | |
| 2025-05-27 | Genentech, Inc. | $985 | Research payment | Cash or cash equivalent | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | 2025 | |
| 2025-05-27 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-05-21 | Celgene Corporation | $1,500 | Research payment | Cash or cash equivalent | Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Regist | 2025 | |
| 2025-05-14 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2025 | |
| 2025-05-13 | Insulet Corporation | $925 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-05-07 | Sumitomo Pharma America, Inc. | $5,545 | Research payment | Cash or cash equivalent | ORGOVYX Drug, PROSTATE CANCER | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2025 |
| 2025-05-07 | Sumitomo Pharma America, Inc. | $30 | Research payment | Cash or cash equivalent | ORGOVYX Drug, PROSTATE CANCER | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2025 |
| 2025-04-29 | PFIZER INC. | $32,029 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2025 | |
| 2025-04-15 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-04-10 | PFIZER INC. | $23,670 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2025 | |
| 2025-04-09 | Sumitomo Pharma America, Inc. | $9,482 | Research payment | Cash or cash equivalent | ORGOVYX Drug, PROSTATE CANCER | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2025 |
| 2025-04-09 | Sumitomo Pharma America, Inc. | $3,886 | Research payment | Cash or cash equivalent | ORGOVYX Drug, PROSTATE CANCER | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2025 |
| 2025-04-08 | Novartis Pharmaceuticals Corporation | $8,288 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety an | 2025 | |
| 2025-04-03 | E.R. Squibb & Sons, L.L.C. | $4,925 | Research payment | Cash or cash equivalent | Connect MM: The Multiple Myeloma Disease Registry. The purpose of the Connect MM Registry is to explore the natural hist | 2025 | |
| 2025-04-02 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-04-01 | PFIZER INC. | $13,018 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2025 | |
| 2025-03-29 | Fisher Scientific Company L.L.C. | $1,294 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-03-26 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-03-26 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2025 | |
| 2025-03-12 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-03-06 | Genentech, Inc. | $1,709 | Research payment | Cash or cash equivalent | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | 2025 | |
| 2025-03-05 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-03-03 | Baxter Healthcare | $3,179 | Debt forgiveness | In-kind items and services | Device, Devices | 2025 | |
| 2025-02-24 | AstraZeneca Pharmaceuticals LP | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | IMFINZI Biological, Oncology | 2025 | |
| 2025-02-05 | Insulet Corporation | $375 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-01-29 | Insulet Corporation | $925 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-01-28 | Genentech, Inc. | $52 | Research payment | Cash or cash equivalent | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | 2025 | |
| 2025-01-23 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-01-21 | Genentech, Inc. | $985 | Research payment | Cash or cash equivalent | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | 2025 | |
| 2025-01-15 | PFIZER INC. | $1,230 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2025 | |
| 2025-01-09 | E.R. Squibb & Sons, L.L.C. | $122,119 | Research payment | Cash or cash equivalent | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibr | 2025 | |
| 2025-01-09 | PFIZER INC. | $9,229 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2025 | |
| 2025-01-01 | Novartis Pharmaceuticals Corporation | $8,050 | Research payment | Cash or cash equivalent | SCEMBLIX Drug, Oncology | A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Stamford, CT, county Western Connecticut Planning Region, CT, state Connecticut; placed by its city name.
| Measure | Place (city or town) Stamford, CT | County Western Connecticut Planning Region, CT | State Connecticut |
|---|---|---|---|
| Population B01003 | 137,144 | 627,071 | 3,624,508 |
| Population, 2020 census P1 | 135,470 | - | 3,605,944 |
| Median age B01002 | 38.4 | 41.5 | 41.1 |
| Under 18 B01001 | 18.4% | 21.8% | 20.2% |
| 65 and over B01001 | 16.2% | 17.4% | 18.5% |
| Households B11001 | 55,291 | 235,379 | 1,434,007 |
| Foreign born B05002 | 31.3% | 23.8% | 15.7% |
| Median household income B19013 | $111,586 | $128,188 | $95,781 |
| Median family income B19113 | $126,493 | $161,625 | $122,706 |
| Per capita income B19301 | $67,068 | $82,266 | $55,915 |
| Poverty rate B17001 | 10.1% | 7.5% | 10.0% |
| Unemployment rate B23025 | 4.9% | 5.3% | 5.6% |
| Civilian labor force B23025 | 81,944 | 346,557 | 1,959,490 |
| Mean commute (minutes) B08013 | 28.5 | 30.8 | 26.5 |
| Bachelor's degree or higher B15003 | 51.7% | 55.5% | 42.5% |
| Housing units B25001 | 58,655 | 251,530 | 1,541,822 |
| Owner-occupied B25003 | 48.8% | 66.4% | 66.5% |
| Renters B25003 | 51.2% | 33.6% | 33.5% |
| Median home value B25077 | $624,400 | $652,900 | $366,900 |
| Median gross rent B25064 | $2,276 | $2,110 | $1,488 |
| White, not Hispanic B03002 | 43.2% | 58.6% | 61.9% |
| Black B03002 | 17.7% | 9.3% | 9.8% |
| Hispanic or Latino B03002 | 28.3% | 20.5% | 18.3% |
| Asian B03002 | 7.3% | 5.4% | 4.7% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 5.1% in Sep 2026 (4.2% a year earlier); per capita personal income $102,307 in 2025, up 33% in five years (+7.1% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Stamford, CT.
Comments